FDA’s 2023 stimulant warning update addressed misuse, addiction, overdose, and sharing medication—not a ban on ADHD treatment. These precautions still matter.
What FDA changed in 2023
On May 11, 2023, FDA announced class-wide updates to prescribing information for prescription stimulants, including amphetamine and methylphenidate products. Its Drug Safety Communication explains that the changes were intended to make warnings about misuse, abuse, addiction, and overdose consistent across the class.
This article revisits that existing safety action. It is not a report of a new restriction announced today, and the action was not a ban on treating ADHD with stimulants. FDA explicitly recognizes that prescription stimulants can be important treatment options for conditions for which they are indicated.
The boxed warning is about serious risks
A boxed warning is a prominent safety warning in a medicine’s prescribing information. FDA required stronger, standardized information about serious risks, including overdose and death when stimulants are misused or abused. Taking your own medication differently than prescribed or taking another person’s prescription both count as nonmedical use.
FDA says the risk rises with higher doses or unapproved ways of taking the medication. The communication also addresses addiction and asks prescribers to assess and monitor each patient’s risk before prescribing and during treatment. This safety warning should not be read as a prediction that every patient receiving appropriate treatment will develop an addiction.
Never share a prescription stimulant
One practical point in the FDA update is unusually direct: patients should never share their prescription stimulants with anyone. A medication prescribed for one person is not automatically appropriate for someone else, even when they describe similar attention problems.
FDA’s patient guidance includes taking the medicine exactly as prescribed, storing it securely, and properly disposing of unused medication. Ask your pharmacist about storage and local medication take-back options rather than keeping unused prescriptions available for others. Do not take an extra dose or alter how you use the medicine without talking with your prescriber.
Treatment decisions still require an assessment
The warning does not diagnose ADHD, establish which medicine an individual should take, or replace follow-up care. Not every stimulant product is approved for every condition or age group. The FDA update covers a class used for ADHD and, depending on the product, other conditions such as narcolepsy or binge-eating disorder; the exact product’s label matters.
Our editorial interpretation is that a careful treatment discussion should cover benefits, risks, follow-up, safe storage, and alternatives—not just obtaining a prescription. Ask how the clinic confirms a diagnosis, reviews other medicines and substance use history, monitors treatment, and responds to side effects. These questions are starting points for care, not a personalized treatment plan.
Where to go next
Discuss concerns with your prescribing clinician or pharmacist rather than stopping, changing, or sharing medication on your own. For a suspected overdose or another immediate medical emergency, call 911. You can find psychiatric clinics or review our psychiatric condition guides before arranging an evaluation.
Source check: October 13, 2026. Written and reviewed by the Psychiatry Clinics editorial team against FDA’s May 11, 2023, safety communication and accompanying labeling-update statement.
This page is informational and is not medical advice.
More reporting on medication safety.
This report is educational and is not medical advice. Coverage, availability and eligibility can change; verify details with the named source or your care team.